{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:55:48Z","timestamp":1774648548747,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_166473"],"award-info":[{"award-number":["310030_166473"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.coph.2019.01.002","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T19:22:14Z","timestamp":1549826534000},"page":"29-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Therapeutic strategies for eosinophilic dermatoses"],"prefix":"10.1016","volume":"46","author":[{"given":"Dagmar","family":"Simon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Uwe","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2019.01.002_bib0005","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.jaci.2007.02.010","article-title":"Eosinophilic disorders","volume":"119","author":"Simon","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2019.01.002_bib0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/ehm.11.81","article-title":"Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field","volume":"5","author":"Valent","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.coph.2019.01.002_bib0015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2019.01.002_bib0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.iac.2015.05.005","article-title":"Eosinophilia in dermatologic disorders","volume":"35","author":"de Graauw","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.coph.2019.01.002_bib0025","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.14888","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coph.2019.01.002_bib0030","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jaci.2017.09.033","article-title":"Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data","volume":"141","author":"Roekevisch","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2019.01.002_bib0035","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ajh.24880","article-title":"World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management","volume":"92","author":"Gotlib","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.coph.2019.01.002_bib0040","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2019.01.002_bib0045","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2019.01.002_bib0050","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1056\/NEJMoa031261","article-title":"Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis","volume":"349","author":"Pl\u00f6tz","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.01.002_bib0055","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.01.002_bib0060","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jaip.2018.04.033","article-title":"Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome","volume":"6","author":"Kuang","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.coph.2019.01.002_bib0065","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.anai.2018.02.017","article-title":"Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab","volume":"120","author":"Kuruvilla","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.coph.2019.01.002_bib0070","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.coph.2019.01.002_bib0075","unstructured":"Simon D, Yousefi S, Cazzaniga S, B\u00fcrgler C, Radonjic S, Houriet C, Heidemeyer K, Kl\u00f6tgen HW, Kozlowski E, Borradori L, Simon HU: Anti-IL-5 therapy in bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study. [submitted for publication]."},{"key":"10.1016\/j.coph.2019.01.002_bib0080","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2019.01.002_bib0085","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2019.01.002_bib0090","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.01.002_bib0095","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2011.05.032","article-title":"IL-5 receptor alpha levels in patients with marked eosinophilia or mastocytosis","volume":"128","author":"Wilson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2019.01.002_bib0100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11899-018-0448-8","article-title":"Diagnosis and novel approaches to the treatment of hypereosinophilic syndromes","volume":"13","author":"Dispenza","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.coph.2019.01.002_bib0105","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jaci.2007.01.023","article-title":"Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies","volume":"119","author":"von Gunten","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2019.01.002_bib0110","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jaip.2017.10.016","article-title":"Successful intravenous immunoglobulin treatment in pediatric severe DRESS syndrome","volume":"6","author":"Marcus","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.coph.2019.01.002_bib0115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bcmd.2017.01.008","article-title":"The targeted eosinophil-lowering effects of dexpramipexole in clinical studies","volume":"63","author":"Dworetzky","year":"2017","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.coph.2019.01.002_bib0120","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2018-02-835330","article-title":"Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes","volume":"132","author":"Panch","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.coph.2019.01.002_bib0125","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.01.002_bib0130","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1146\/annurev-pharmtox-010814-124407","article-title":"Novel targeted therapies for eosinophil-associated diseases and allergy","volume":"55","author":"Radonjic-Hoesli","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.coph.2019.01.002_bib0135","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","article-title":"Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib","volume":"137","author":"King","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2019.01.002_bib0140","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2019.01.002_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2019.01.002_bib0150","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2019.01.002_bib0155","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3109\/10428190903216770","article-title":"Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center","volume":"50","author":"Querfeld","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.coph.2019.01.002_bib0160","doi-asserted-by":"crossref","first-page":"117ra7","DOI":"10.1126\/scitranslmed.3003008","article-title":"Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients","volume":"4","author":"Clark","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2019.01.002_bib0165","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/cup.12800","article-title":"Histopathologic spectrum of hypersensitivity reactions associated with anti-CD52 therapy (alemtuzumab)","volume":"43","author":"Clark","year":"2016","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.coph.2019.01.002_bib0170","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.01.002_bib0175","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.01.002_bib0180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2019.01.002_bib0185","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","article-title":"Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies","volume":"70","author":"Hanania","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.coph.2019.01.002_bib0190","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2019.01.002_bib0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2019.01.002_bib0200","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/mi.2008.15","article-title":"Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses","volume":"1","author":"Blanchard","year":"2008","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.coph.2019.01.002_bib0205","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1568010033344480","article-title":"Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications","volume":"2","author":"Amerio","year":"2003","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"10.1016\/j.coph.2019.01.002_bib0210","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1398-9995.2011.02694.x","article-title":"Distinct eosinophil cytokine expression patterns in skin diseases \u2014 the possible existence of functionally different eosinophil subpopulations","volume":"66","author":"Roth","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.coph.2019.01.002_bib0215","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.4049\/jimmunol.163.7.3976","volume":"163","author":"Ying","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2019.01.002_bib0220","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1365-2133.2000.03599.x","article-title":"Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia","volume":"143","author":"Wakugawa","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2019.01.002_bib0225","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/1346-8138.13287","article-title":"Eosinophilic pustular folliculitis: a published work-based comprehensive analysis of therapeutic responsiveness","volume":"43","author":"Nomura","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.coph.2019.01.002_bib0230","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/j.1398-9995.2012.02868.x","article-title":"Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps","volume":"67","author":"Morshed","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.coph.2019.01.002_bib0235","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.01.002_bib0240","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor a antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.01.002_bib0245","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/jid.2015.106","article-title":"IL-31 induces chemotaxis, calcium mobilization, release of reactive oxygen species, and CCL26 in eosinophils, which are capable to release IL-31","volume":"135","author":"Kunsleben","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2019.01.002_bib0250","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2340\/00015555-2951","article-title":"Eosinophils are a major source of interleukin-31 in bullous pemphigoid","volume":"98","author":"R\u00fcdrich","year":"2018","journal-title":"Acta Derm Venereol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147148921830170X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147148921830170X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:50:24Z","timestamp":1761461424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147148921830170X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":50,"alternative-id":["S147148921830170X"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2019.01.002","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic strategies for eosinophilic dermatoses","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2019.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}